Cargando…

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells

The main protease, M(pro), of SARS-CoV-2 is required to cleave the viral polyprotein into precise functional units for virus replication and pathogenesis. Here, we report quantitative reporters for M(pro) function in living cells in which protease inhibition by genetic or chemical methods results in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moghadasi, Seyed Arad, Esler, Morgan A., Otsuka, Yuka, Becker, Jordan T., Moraes, Sofia N., Anderson, Constance B., Chamakuri, Srinivas, Belica, Christopher, Wick, Chloe, Harki, Daniel A., Young, Damian W., Scampavia, Louis, Spicer, Timothy P., Shi, Ke, Aihara, Hideki, Brown, William L., Harris, Reuben S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239272/ https://www.ncbi.nlm.nih.gov/pubmed/35471084 http://dx.doi.org/10.1128/mbio.00784-22

Ejemplares similares

Gain-of-function assay for SARS-CoV-2 M(pro) inhibition in living cells
por: Moghadasi, Seyad Arad, et al.
Publicado: (2020)

Studies on antiviral resistant SARS-CoV-2 Mpro mutants
por: Esler, Morgan A., et al.
Publicado: (2023)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Rapid resistance profiling of SARS-CoV-2 protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

Rapid resistance profiling of SARS-CoV-2 protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Mitochondrial double-stranded RNA triggers induction of the antiviral DNA deaminase APOBEC3A and nuclear DNA damage
por: Wick, Chloe, et al.
Publicado: (2023)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
por: Moghadasi, Seyed Arad, et al.
Publicado: (2023)

“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"
por: Bhowmik, Deep, et al.
Publicado: (2021)

Pro108Ser mutation of SARS-CoV-2 3CL(pro) reduces the enzyme activity and ameliorates the clinical severity of COVID-19
por: Abe, Kodai, et al.
Publicado: (2022)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Engineering a novel endopeptidase based on SARS 3CL(pro)
por: Kuo, Chih-Jung, et al.
Publicado: (2009)

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2021)

Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19
por: Roe, Molly K., et al.
Publicado: (2021)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

QM/QM studies for Michael reaction in coronavirus main protease (3CL(Pro))
por: Taranto, Alex G., et al.
Publicado: (2008)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3′-Deoxy-3′,4′-didehydro-cytidine Nucleotide from RNA
por: Moeller, Nicholas H., et al.
Publicado: (2022)

Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B
por: Shi, Ke, et al.
Publicado: (2019)

Body weight gain during adulthood and uterine myomas: Pró-Saúde Study
por: Boclin, Karine de Lima Sírio, et al.
Publicado: (2015)

DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M(pro) inhibitors
por: Chamakuri, Srinivas, et al.
Publicado: (2021)

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel structure-based design approach to treat COVID-19
por: Rajpoot, Sajjan, et al.
Publicado: (2020)

Effects of diarylbutane lignans from Schisandra chinensis fruit on SARS-CoV-2 3CL(pro) and PL(pro) and their in vitro anti-inflammatory properties
por: Li, Bin, et al.
Publicado: (2023)

Coronavirus 3CL(pro )proteinase cleavage sites: Possible relevance to SARS virus pathology
por: Kiemer, Lars, et al.
Publicado: (2004)

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition
por: Ryu, Young Bae, et al.
Publicado: (2010)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Machine learning prediction of 3CL(pro) SARS-CoV-2 docking scores
por: Bucinsky, Lukas, et al.
Publicado: (2022)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

QSAR and molecular docking studies of isatin and indole derivatives as SARS 3CL(pro) inhibitors
por: Soleymani, Niousha, et al.
Publicado: (2023)

Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CL(pro) substrate degradome
por: Pablos, Isabel, et al.
Publicado: (2021)

Schaftoside inhibits 3CL(pro) and PL(pro) of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
por: Yi, Yang, et al.
Publicado: (2022)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system
por: Costacurta, Francesco, et al.
Publicado: (2023)

Comparision of Ambu AuraGain™ and LMA(®) ProSeal in children under controlled ventilation
por: Joshi, Reesha, et al.
Publicado: (2018)

Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome
por: Hancox, J. C., et al.
Publicado: (2023)

Ancestral APOBEC3B Nuclear Localization Is Maintained in Humans and Apes and Altered in Most Other Old World Primate Species
por: Auerbach, Ashley A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s6idhdqac34d07bj8mq3lodhk4